Gadofosveset trisodium

钆膦维司三钠

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameGadofosveset trisodium
Drug Alias Namegadofosveset钆磷维塞三钠gadofosvesetumAngioMARKAblavar +[9] 
ClassificationDiagnostic agent (In vivo)Small molecules
Mechanisms of ActionMagnetic resonance imaging enhancers
TargetsNot applicable
Therapy Area/IndicationsContrast agentsPeripheral Vascular DiseasesIntermittent Claudication +[6] 
Global Approved IndicationsContrast agentsPeripheral Vascular Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2008/12/22
Country/TerritoryUnited StatesMexicoAustria +[8] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesEpix
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)Bayer AGLantheus Medical Imaging Inc
Active IndicationsN/A
Inactive IndicationsContrast agentsPeripheral Vascular DiseasesIntermittent Claudication +[6] 

Other Information

ATC CodeV08CA11
Related LinksWikipediaDrugBankKEGG